Beyond binding – iPSC-based functional safety screening for oncology modalities
Thursday, January 22 at 15:00 GMT | 16:00 CET | 10:00 EST | 07:00 PST
Biologics and cell-based therapeutics are expanding rapidly across oncology, yet early detection of safety liabilities remains a critical challenge. Off-target interactions and low-level antigen expression in healthy tissues can lead to severe clinical setbacks.
Recent FDA guidance emphasizes the need for human-relevant in vitro systems to assess functional toxicities before entering clinical trials. Induced pluripotent stem cell (iPSC)-derived models provide a reproducible, scalable solution for multi-tissue safety evaluation, including cardiac risk assessment.
In this webinar, industry experts will explore current challenges in oncology safety testing and the evolving regulatory landscape. They will introduce a novel iPSC-derived multi-tissue functional safety screening platform and demonstrate how comprehensive kinetic cardiac profiling can mitigate risk prior to clinical development, supported by case studies on antibody-drug conjugates (ADCs) and kinase inhibitors.
Who should attend?
- Big pharma: in vitro translational, pharmacology, toxicology and safety teams
- Biotechnology companies: in vitro translational, pharmacology, toxicology and safety teams
- Regulatory agencies employees: EMA and FDA
- Non-profit research organizations/foundations in oncology
- Oncology advocatory groups
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
Speakers
Featured products
Request Quote for All ProductsWhat will this webinar cover?
- Understand the current challenges and regulatory expectations for in vitro safety testing in oncology drug development.
- Learn how iPSC-derived multi-tissue models overcome limitations of traditional systems and improve translational relevance.
- Gain insights into integrating multi-tissue safety screening into drug development workflows and support regulatory alignment.
- Discover how early cardiac safety profiling can guide program decision and inform risk mitigation.
Join the webinar to get answers to these questions:
- What are the key challenges and regulatory expectations for in vitro oncology safety testing?
- How do iPSC-derived multi-tissue models improve translational relevance over traditional systems?
- How can multi-tissue safety screening be integrated into existing drug development workflows?
- In what ways can these approaches support alignment with evolving regulatory guidance?
- How does early cardiac safety profiling inform program decisions and risk mitigation strategies?